Metabiomics

10/01/2024

Opioids can be effective for pain relief when used as prescribed, but they also carry the risk of dependence, misuse, and addiction, with factors like genetics playing a role. AvertD, an FDA-approved test, uses DNA from buccal swabs to determine whether they have a specific set of genetic variants that may be associated with an elevated genetic risk of developing opioid use disorder (OUD). AvertD can be a crucial part of assessing a patient’s risk for OUD within a comprehensive clinical evaluation.

Learn more about AvertD by SOLVD Health: https://avertdtest.com/

09/02/2021

Metabiomics is hiring a bioinformatics engineer. Join our team in San Diego to work on a , and driven test to detect and prevent colon cancer!

Posted 2:16:43 AM. At Metabiomics, a Joint Venture with SOLVD Health (formerly Prescient Medicine), we’re focused on…See this and similar jobs on LinkedIn.

11/20/2020

Metabiomics is hiring a Director of Assay Development to accelerate the development of our microbiome diagnostics platform and NGS lab. https://buff.ly/333zYTI

11/12/2020

New Recommendations for How Often to Repeat Colonoscopy Following Polypectomy

A new multisociety guideline was recently released suggesting that for many patients, the interval between colonoscopies following polyp resection is less than previously recommended. Cecelia Zhang, MD, Duke University, and Maylyn Martinez, MD, University of Chicago, discuss the new guideline.

10/29/2020

Gamers are helping map the human gut Microbiome! AI+Gamer-driven analytics.

Gearbox Studios CEO Randy Pitchford and videogame science company MMOS cofounder Attila Szantner discuss the design and deployment decisions that drew 1.6 million players to their gene sequencing alignment puzzle game, and how "citizen science" games can help advance data-driven research.

08/14/2020

The majority of colon cancers can be prevented with screening programs that deploy colonoscopy and non-invasive tests. There's still a need for more sensitive stool tests, which is exactly what Metabiomics is focused on.

Less may be more when it comes to colonoscopies. While it’s a highly effective screening tool, the invasive colonoscopy is uncomfortable to prepare for. That may be why so many take a pass on it.&n…

06/25/2020

Prescient Metabiomics announced today a collaboration with the Harvard microbiome center to study microbial biomarkers for detecting colon cancer.

05/06/2020

https://buff.ly/35HvQcf "By the end of this decade, I predict that these early detection tests will impact cancer survival to a greater extent than therapies."

In the future, diagnostic technologies will matter just as much as therapeutics and significantly improve the deployment of healthcare spending.

12/17/2019

At the intersection of the gut microbiome, NGS sequencing, and AI-Driven analytics emerges a breakthrough test for colon cancer prevention. and announce new collaboration.

CARLSBAD, Calif., Dec. 17, 2019 /PRNewswire/ — Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., and CoreBiome, a wholly owned subsidiary of OraSure Technologies, Inc., announced today a collaboration to develop a new test called LifeKit® Prevent, which may represent a mic...

09/05/2019

Prescient Metabiomics LifeKit Prevent Colon Cancer Test has been granted a Breakthrough Designation by the FDA.

Prescient Metabiomics receives FDA Breakthrough designation for metagenomics colon cancer test, LifeKit Prevent.